Harpoon Therapeutics HARP Stock
Harpoon Therapeutics Price Chart
Harpoon Therapeutics HARP Financial and Trading Overview
| Harpoon Therapeutics stock price | 23.01 USD |
| Previous Close | 0.71 USD |
| Open | 0.7 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 3000 |
| Day's Range | 0.69 - 0.75 USD |
| 52 Week Range | 0.54 - 3.36 USD |
| Volume | 349.56K USD |
| Avg. Volume | 209.84K USD |
| Market Cap | 27.98M USD |
| Beta (5Y Monthly) | 1.538195 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.33 USD |
HARP Valuation Measures
| Enterprise Value | -12558975 USD |
| Trailing P/E | N/A |
| Forward P/E | -3.5433333 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.808714 |
| Price/Book (mrq) | 39.16316 |
| Enterprise Value/Revenue | -0.363 |
| Enterprise Value/EBITDA | 0.223 |
Trading Information
Harpoon Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.538195 |
| 52-Week Change | -63.52% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.36 USD |
| 52 Week Low | 0.54 USD |
| 50-Day Moving Average | 0.69 USD |
| 200-Day Moving Average | 0.86 USD |
HARP Share Statistics
| Avg. Volume (3 month) | 209.84K USD |
| Avg. Daily Volume (10-Days) | 245.44K USD |
| Shares Outstanding | 37.6M |
| Float | 25.56M |
| Short Ratio | 1.8 |
| % Held by Insiders | 1.04% |
| % Held by Institutions | 57.79% |
| Shares Short | 282.99K |
| Short % of Float | 1.09% |
| Short % of Shares Outstanding | 0.75% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -169.83% |
| Operating Margin (ttm) | -169.91% |
| Gross Margin | -118.94% |
| EBITDA Margin | -162.93% |
Management Effectiveness
| Return on Assets (ttm) | -34.45% |
| Return on Equity (ttm) | -279.093% |
Income Statement
| Revenue (ttm) | 34.59M USD |
| Revenue Per Share (ttm) | 1.01 USD |
| Quarterly Revenue Growth (yoy) | 45.30% |
| Gross Profit (ttm) | -49478000 USD |
| EBITDA | -56362000 USD |
| Net Income Avi to Common (ttm) | -58748000 USD |
| Diluted EPS (ttm) | -1.84 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 61.39M USD |
| Total Cash Per Share (mrq) | 1.63 USD |
| Total Debt (mrq) | 20.85M USD |
| Total Debt/Equity (mrq) | 2916.22 USD |
| Current Ratio (mrq) | 1.446 |
| Book Value Per Share (mrq) | 0.019 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -83230000 USD |
| Levered Free Cash Flow (ttm) | -40614876 USD |
Profile of Harpoon Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 131 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 650 443 7400 |
| Website | https://www.harpoontx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 45 |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Q&A For Harpoon Therapeutics Stock
What is a current HARP stock price?
Harpoon Therapeutics HARP stock price today per share is 23.01 USD.
How to purchase Harpoon Therapeutics stock?
You can buy HARP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Harpoon Therapeutics?
The stock symbol or ticker of Harpoon Therapeutics is HARP.
Which industry does the Harpoon Therapeutics company belong to?
The Harpoon Therapeutics industry is Biotechnology.
How many shares does Harpoon Therapeutics have in circulation?
The max supply of Harpoon Therapeutics shares is 21.4M.
What is Harpoon Therapeutics Price to Earnings Ratio (PE Ratio)?
Harpoon Therapeutics PE Ratio is 0.00000000 now.
What was Harpoon Therapeutics earnings per share over the trailing 12 months (TTM)?
Harpoon Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Harpoon Therapeutics company belong to?
The Harpoon Therapeutics sector is Healthcare.
Harpoon Therapeutics HARP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}